PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25655312-6 2015 Concomitant treatment with cyclophosphamide and temozolomide resulted in less CD4(+) decrease (P = 0.041) than cyclophosphamide only. Cyclophosphamide 27-43 CD4 molecule Homo sapiens 78-81 28132769-3 2017 Intravenous administration of cyclophosphamide (37.5 mg/kg body weight) resulted in immunosuppresion induction, as significant drops were observed in blood leukocytes and lymphocyte subset counts (CD2+, CD4+, CD8+, CD19+), lasting 3-10 days after its administration. Cyclophosphamide 30-46 CD4 molecule Homo sapiens 203-206 25950695-0 2015 The CD4 Lymphocyte Count is a Better Predictor of Overall Infection Than the Total Lymphocyte Count in ANCA-Associated Vasculitis Under a Corticosteroid and Cyclophosphamide Regimen: A Retrospective Cohort. Cyclophosphamide 157-173 CD4 molecule Homo sapiens 4-7 25251877-2 2014 Susceptibility of CD4(+) regulatory T (Treg) cells to the ABCB1-substrate cyclophosphamide (CPA) has been reported. Cyclophosphamide 74-90 CD4 molecule Homo sapiens 18-21 25251877-2 2014 Susceptibility of CD4(+) regulatory T (Treg) cells to the ABCB1-substrate cyclophosphamide (CPA) has been reported. Cyclophosphamide 92-95 CD4 molecule Homo sapiens 18-21 25251877-6 2014 In vitro, the ABCB1-substrate CPA was cytotoxic for Treg cells at a 100-fold lower dose than for nonregulatory counterparts, and, inversely, verapamil, an inhibitor of ABC transporters, increased CPA-toxicity in nonregulatory CD4(+) T cells but not Treg cells. Cyclophosphamide 30-33 CD4 molecule Homo sapiens 226-229 22349930-10 2012 Four weeks of CYC or MMF treatment led to a significant increase in CD3+CD4+ T cells (P < 0.05). Cyclophosphamide 14-17 CD4 molecule Homo sapiens 72-75 24376696-0 2013 Human CD4+CD25+ regulatory T cells are sensitive to low dose cyclophosphamide: implications for the immune response. Cyclophosphamide 61-77 CD4 molecule Homo sapiens 6-9 23507054-8 2013 We recommend especially to monitor neutrophiles, lymphocytes and if needed CD3-, CD4- and CD8-cell counts in patients receiving steroids and cyclophosphamide or other cytotoxic agents. Cyclophosphamide 141-157 CD4 molecule Homo sapiens 81-84 25430593-10 2014 CONCLUSIONS: Cyclophosphamide pulse therapy was associated with a significant increase of the CD4(+) CD25(high) FOXP3(+) Tregs in patients with active LN and NPSLE. Cyclophosphamide 13-29 CD4 molecule Homo sapiens 94-97 22539294-5 2012 Our data indicate that adoptive transfer of donor-derived T-cell receptor (TCR) alphabeta(+) CD3(+) CD4(-) CD8(-) NK1.1(-) (double negative, DN) Treg cells prior to C57BL/6 to BALB/c BM transplantation, in combination with cyclophosphamide, induced a stable-mixed chimerism and acceptance of C57BL/6 skin allografts but rejection of third-party C3H (H-2k) skin grafts. Cyclophosphamide 223-239 CD4 molecule Homo sapiens 100-103 21054711-0 2010 Therapeutic hotline: Primary cutaneous CD4 + small/medium-sized pleomorphic T cell lymphoma coexisting with myelodysplastic syndrome transforming into chronic myelomonocytic leukemia successfully treated with cyclophosphamide. Cyclophosphamide 209-225 CD4 molecule Homo sapiens 39-42 22285846-3 2012 Cyclophosphamide (CY) has been demonstrated to be effective in counteracting CD4(+)CD25(+) Treg activity. Cyclophosphamide 0-16 CD4 molecule Homo sapiens 77-80 22285846-3 2012 Cyclophosphamide (CY) has been demonstrated to be effective in counteracting CD4(+)CD25(+) Treg activity. Cyclophosphamide 18-20 CD4 molecule Homo sapiens 77-80 20857100-7 2011 Analysis of peripheral blood samples from patients prior and during fludarabine/cyclophosphamide therapy revealed rapid and sustained reduction of tumour cells but also of CD4(+) and CD8(+) T cells. Cyclophosphamide 80-96 CD4 molecule Homo sapiens 172-175 20964639-6 2010 On the other hand, using cyclophosphamide and gemcitabine, we demonstrated that regulatory/suppressor CD4(+) CD25(+) forkhead boxP3(+) and GR-1(+) CD11b(+) cells do not play a major role in the establishment or the maintenance of endotoxin tolerance, a central mechanism for inducing an immunosuppression state. Cyclophosphamide 25-41 CD4 molecule Homo sapiens 102-105 21054711-4 2010 We report a case of primary cutaneous CD4 + small/medium-sized pleomorphic T cell lymphoma accompanied with myelodysplastic syndrome successfully treated with cyclophosphamide. Cyclophosphamide 159-175 CD4 molecule Homo sapiens 38-41 20338811-0 2010 CD4+FOXP3+ regulatory T cell depletion by low-dose cyclophosphamide prevents recurrence in patients with large condylomata acuminata after laser therapy. Cyclophosphamide 51-67 CD4 molecule Homo sapiens 0-3 20501849-0 2010 Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cyclophosphamide 70-86 CD4 molecule Homo sapiens 23-26 20501849-7 2010 On the other hand, the transfection of miR-142-3p inhibitor or the addition of soluble CD39 to the cultured CD4(+)CD25(-) T cells resulted in the decrease of intracellular ATP levels and increase of sensitivity of conventional T cells to low-dose CY. Cyclophosphamide 247-249 CD4 molecule Homo sapiens 108-111 18199598-9 2008 Treatment with glucocorticoids and cyclophosphamide reduced CD4(+)CD25(-)Foxp3(+) T cells in 8 of 10 patients with active disease. Cyclophosphamide 35-51 CD4 molecule Homo sapiens 60-63 19590872-2 2010 We observed that Cy administration resulted in expansion of tumor antigen-specific T cells and transient depletion of CD4(+)Foxp3(+) regulatory T cells (Tregs). Cyclophosphamide 17-19 CD4 molecule Homo sapiens 118-121 20139774-0 2010 Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. Cyclophosphamide 9-25 CD4 molecule Homo sapiens 88-91 18443965-1 2008 We report a case of a previously healthy 31 year old woman diagnosed with Stage IIIA follicular lymphoma treated with fludarabine in combination with cyclophosphamide and rituximab who presented seven years after the completion of therapy with CD4 count depression, panhypogammaglobulinema and a history of recurrent sinus infections. Cyclophosphamide 150-166 CD4 molecule Homo sapiens 244-247 17854912-0 2007 High dose cyclophosphamide preferentially targets naive T (CD45/CD4/RA+) cells in CIDP and MS patients. Cyclophosphamide 10-26 CD4 molecule Homo sapiens 59-62 17956583-0 2007 Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Cyclophosphamide 136-152 CD4 molecule Homo sapiens 12-15 15591121-0 2005 Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Cyclophosphamide 102-118 CD4 molecule Homo sapiens 14-17 16960692-0 2007 Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cyclophosphamide 11-27 CD4 molecule Homo sapiens 57-60 34329754-0 2021 Increased infections and delayed CD4+ T-cell but faster B-cell Immune Reconstitution after Posttransplant Cyclophosphamide Compared to Conventional GVHD prophylaxis in Allogeneic Transplantation. Cyclophosphamide 106-122 CD4 molecule Homo sapiens 33-36 14698862-0 2004 Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8+ T cells in secondary progressive multiple sclerosis. Cyclophosphamide 0-16 CD4 molecule Homo sapiens 27-30 14698862-10 2004 Furthermore, therapy with cyclophosphamide increases IL-4-producing CD4(+) T cells and reverses the increase in IFN-gamma-producing CD8(+) T cells. Cyclophosphamide 26-42 CD4 molecule Homo sapiens 68-71 8578886-6 1995 Intractable cases (under daily cyclophosphamide + prednisolone) may profit from additional high dose IVIG therapy or from monoclonal antibodies against CD4 and CDw52 molecules. Cyclophosphamide 31-47 CD4 molecule Homo sapiens 152-155 1672870-3 1991 Cyclophosphamide/ACTH infusions significantly decreased the proportion of peripheral blood CD4+ T cells at 2, 6 and 12 months following treatment while there was a tendency for increased CD8 expression. Cyclophosphamide 0-16 CD4 molecule Homo sapiens 91-94 1672870-6 1991 The only T cell populations predictive of improvement were percentages of either CD3+ or CD4+ cells where increased percentages of either these populations at 2 months following cyclophosphamide/ACTH infusions were associated with improvement at both 6 and 12 months. Cyclophosphamide 178-194 CD4 molecule Homo sapiens 89-92 2830969-0 1988 Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cyclophosphamide 19-35 CD4 molecule Homo sapiens 90-93 35433455-14 2022 CellMinor analysis showed that the CD4 mRNA expression level dramatically climbed with increased sensitivity of tumor cells to NAC drugs such as cyclophosphamide, cisplatin, and carboplatin (p"s < 0.05). Cyclophosphamide 145-161 CD4 molecule Homo sapiens 35-38 2830969-6 1988 Treatment of melanoma patients with CY plus vaccine resulted in a progressive fall in the proportion of CD4+ T-cells expressing the 2H4 (CD45) antigen, which identifies inducers of suppression. Cyclophosphamide 36-38 CD4 molecule Homo sapiens 104-107 2830969-7 1988 The reduction of CD4+, 2H4+ T-cells did not become apparent until day 28 after the first dose of CY and reached statistical significance only on days 49 (21 days after the second dose) and 105 (21 days after the fourth dose) (mean changes +/- SE: day 49, -5.4 +/- 1.4%, P less than 0.01; day 105, -9.1 +/- 2.2%, P less than 0.01; t test for nonindependent samples). Cyclophosphamide 97-99 CD4 molecule Homo sapiens 17-20 2957983-3 1987 Cyclophosphamide was administered at monthly intervals, escalating the dose until there was a significant reduction in both the number of blood B lymphocytes and helper/inducer (CD4) T cells of 14 patients with chronic progressive MS. Cyclophosphamide 0-16 CD4 molecule Homo sapiens 178-181 2950845-1 1987 Cyclophosphamide was administered to 14 patients with chronic progressive multiple sclerosis on an intermittent escalating dosage schedule adjusted to maintain numbers of peripheral blood B lymphocytes and helper/inducer (CD4) T cells below the fifth percentile of the normal population. Cyclophosphamide 0-16 CD4 molecule Homo sapiens 222-225 2960008-3 1987 It appears that Cyclophosphamide is able to correct the CD4/CD8 ratio imbalance observed in most MS patients and that this correction is generally associated with a beneficial effect on the disease. Cyclophosphamide 16-32 CD4 molecule Homo sapiens 56-59 30890769-0 2019 Donor-derived CD4+/CCR7+ T-cell impact on acute GVHD incidence following haplo-HCT after reduced intensity conditioning and posttransplant cyclophosphamide. Cyclophosphamide 139-155 CD4 molecule Homo sapiens 14-17 33545713-0 2021 A combination of cyclophosphamide, interleukin-2 allow CD4+ T cells converted to Tregs to control scurfy syndrome. Cyclophosphamide 17-33 CD4 molecule Homo sapiens 55-58 30186977-4 2018 Discussion: The treatment protocol aims to reverse immune evasion of the tumor through a radiotherapy-induced self-vaccination effect, suppression of CD4+ CD25+ FoxP3+ regulatory T-cell function by metronomic cyclophosphamide, and effector T-cell reactivation owing to the inhibition of the PD-1-PD-L1 axis by avelumab.The immunologic interplay induced by the proposed combined treatment may theoretically improve the activity of avelumab without increasing its toxicity profile.Finally, an ancillary translational study will be extended to all the patients" population. Cyclophosphamide 209-225 CD4 molecule Homo sapiens 150-153